Floatz logo

Alemtuzumab

Telomere Syndrome

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinsmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Telomere Syndrome cohort.

Asset / SponsorPhaseRating
Danazol
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2B
Melphalan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Tacrolimus
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Nandrolone Decanoate
University of Sao Paulo
Phase 1/2CCC

Same molecule, other indications

Alemtuzumab is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative · Phase 2
71 / 100
View asset →
chronic myeloid leukemiaActive
BB
Indicative · Phase 2/3
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →